Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Gross Margin (2016 - 2025)

Historic Gross Margin for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 55.76%.

  • International Stem Cell's Gross Margin rose 4600.0% to 55.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.86%, marking a year-over-year increase of 5100.0%. This contributed to the annual value of 58.57% for FY2024, which is 5900.0% down from last year.
  • Latest data reveals that International Stem Cell reported Gross Margin of 55.76% as of Q3 2025, which was up 4600.0% from 62.12% recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Gross Margin ranged from a high of 64.58% in Q2 2022 and a low of 53.25% during Q4 2022
  • Moreover, its 5-year median value for Gross Margin was 59.53% (2024), whereas its average is 58.95%.
  • The largest annual percentage gain for International Stem Cell's Gross Margin in the last 5 years was 65900bps (2022), contrasted with its biggest fall of -68700bps (2022).
  • Quarter analysis of 5 years shows International Stem Cell's Gross Margin stood at 60.12% in 2021, then fell by -11bps to 53.25% in 2022, then grew by 2bps to 54.31% in 2023, then rose by 10bps to 59.53% in 2024, then decreased by -6bps to 55.76% in 2025.
  • Its Gross Margin was 55.76% in Q3 2025, compared to 62.12% in Q2 2025 and 53.41% in Q1 2025.